• Wondering whether Stevanato Group at around US$19 still offers value, or if the recent enthusiasm has already been priced in? This article focuses squarely on what that price tag may imply.
• The stock has had a sharp move recently, with a 16.9% return over the past week and 37.8% over the past month, even though it still shows a 7.7% decline year to date and a 12.6% decline over the last year.
• Recent coverage has focused on Stevanato Group as part of broader market conversations around life sciences suppliers, product pipelines and capital allocation, which helps explain why sentiment can shift quickly. For investors, these stories can change how risk and growth potential are perceived even when the underlying business profile is relatively stable.
• On Simply Wall St's valuation framework, Stevanato Group scores a 4 out of 6. The rest of this article will break down what that means across different valuation approaches and then finish with a way to go beyond the numbers to understand the story behind that score.

Approach 1: Stevanato Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash Stevanato Group may generate in the future and discounts them back to today, aiming to arrive at an estimate of what the business might be worth in the present.

For Stevanato Group, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of €76.07 million, so the story here is driven by expectations for improvement rather than current cash generation. Analyst estimates feed into the early years of the forecast, and Simply Wall St then extrapolates further out, with projected free cash flow reaching €860.85 million in 2035 according to the ten year path provided.

When all projected cash flows are discounted back, the intrinsic value comes out at €31.44 per share, compared with a current share price around US$19. This implies an intrinsic discount of 39.6%, which indicates that Stevanato Group stock is trading at a meaningful discount to this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Stevanato Group is undervalued by 39.6%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Stevanato Group Price vs Earnings

For profitable companies, the P/E ratio is a useful shortcut because it directly links what you pay for the stock to the earnings the business is currently generating. It is essentially a quick way to see how many dollars investors are willing to pay today for one dollar of earnings.

What counts as a "normal" or "fair" P/E ratio depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower P/E.

Stevanato Group currently trades on a P/E of 31.57x. That sits below the Life Sciences industry average P/E of 37.13x and also below the peer group average of 58.52x. Simply Wall St’s Fair Ratio for Stevanato Group is 18.90x, which is its proprietary view of what a suitable P/E could be once factors like earnings growth, industry, profit margin, market cap and risk are considered.

The Fair Ratio can be more informative than a simple peer or industry comparison because it is tailored to the company’s own profile rather than using broad group averages. With the current P/E at 31.57x and the Fair Ratio at 18.90x, the stock screens as more expensive than this Fair Ratio implies.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Stevanato Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Stevanato Group’s story to a clear forecast and Fair Value, then compare that to the current price, with the platform updating your Narrative automatically as new earnings or news arrive.

In practice, you pick assumptions for revenue, earnings and margins that match your view, and the Narrative turns these into a Fair Value that can help you decide whether Stevanato Group looks more appealing or less appealing at today’s price.

For example, one investor might lean toward a more upbeat Stevanato Group Narrative that lines up with a US$32.0 Fair Value. Another might choose a more cautious Narrative that sits closer to US$17.5. Both can see in the Community page how those different stories translate into numbers and how the gap between Fair Value and price changes over time.

For Stevanato Group, here are previews of two leading Stevanato Group Narratives:

Fair value in this Narrative: US$24.72 per share

Implied discount to this fair value at a US$19.00 share price: about 23.1%

Revenue growth in this Narrative: 9.0% a year

• Analysts building this Narrative see growing demand for high value biologics and self administration formats supporting Stevanato Group's earnings power over time.
• They expect margin improvement helped by higher value product mix and better utilisation of newer facilities, within a 10.43% discount rate framework.
• The fair value of US$24.72 reflects assumptions for revenue of €1.5b and earnings of €244.0m by 2029, with a P/E of 31.9x on those earnings.

Fair value in this Narrative: US$17.50 per share

Implied premium to this fair value at a US$19.00 share price: about 8.6%

Revenue growth in this Narrative: 9.0% a year

• This more cautious Narrative focuses on risks from higher regulatory costs, local competition and new drug delivery formats that could limit demand for Stevanato Group's core products.
• It assumes similar revenue and earnings outcomes by 2029 to the bullish case, but applies a lower 22.5x P/E multiple and a 10.45% discount rate.
• The result is a fair value of US$17.50, closer to the lower end of the analyst price target range between US$17.50 and US$32.00.

If you want to see how these stories look in full, and how other investors are framing the trade off between upside and risk, you can compare the community's range of Narratives side by side for Stevanato Group in one place using the See what the community is saying about Stevanato Group.

Do you think there's more to the story for Stevanato Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.